Managing access to advanced therapy medicinal products: Challenges for NHS Wales

摘要

Advanced Therapy Medicinal Products (ATMPs), which include gene, somatic cell therapies and tissue-engineered medicines, have the potential to transform current care pathways by offering durable and potentially curative outcomes. However, they are exceptionally expensive, with prices exceeding 1m pound per patient in some cases. With an expectation that a large number of ATMPs will soon gain marketing authorisation (global market is estimated to reach 9bn pound to 14bn pound by 2025), healthcare payers and providers face a number of challenges to facilitate patient access to this new category of medicines.